What is CG Oncology's market cap?

CG Oncology (CGON) has a market capitalization of $6.5B and trades on NASDAQ.

What is CG Oncology's revenue and profitability?

CG Oncology generated $5.1M in trailing twelve-month revenue with a net loss of $186.7M, representing a net margin of -3682.6%, with free cash flow of -$160.4M. These figures are based on the Q1 2026 filing.

Who are CG Oncology's competitors?

CG Oncology's key competitors include ImmunityBio Inc., Johnson & Johnson, UroGen Pharma, Inc., and others. These companies compete in similar markets and product categories.

Who does CG Oncology partner with?

CG Oncology's notable partners include Kissei Pharmaceutical Co., Ltd., Lepu Biotech Co., Ltd., Merck & Co., Inc., and others.

What subsidiaries does CG Oncology have?

CG Oncology's subsidiaries include Biovire.

Where is CG Oncology headquartered?

CG Oncology is headquartered in United States of America and employs approximately 61 people. It has been publicly traded since 2024.

CG Oncology

CGON

CG Oncology is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing oncolytic immunotherapies for bladder cancer.

Market cap

$6.48B+216%

Revenue$5.1M+666%

Net income-$186.7M-76.9%

Free cash flow-$160.4M-95.1%

EPS (diluted)-$2.33-54.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 8, 2026

Revenue$1.1MBeat by $630.0K EPS-$0.71Miss by $0.13

Read the full report

Next report

Aug 7, 2026 (In 1 week)

Revenue estimate$360.8K

EPS estimate-$0.70

Financials

Q1 2026

Income statement

See full

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

See full

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

See full

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation & ratios

Valuation

See full

Market cap$6.48B+216%

Enterprise value$6.46B+230%

P/S1,278.8×-2,299×

Profitability

See full

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

See full

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Segments

By product

See full

Commercial And Development Revenue$1.1M—

License And Collaboration Revenue$14.0K-73.1%

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Gilead Sciences$162.05B+15.3%

ImmunityBio, Inc.$7.3B+213%

CG Oncology$6.5B+229%

UroGen Pharma$2.0B+131%

Relmada Therapeutics, Inc.$545.9M+2,468%

Protara Therapeutics, Inc.$227.1M+75.7%

enGene Therapeutics Inc. $117.9M-36.6%

By revenue growth

CG Oncology+666%

ImmunityBio, Inc.+352%

UroGen Pharma+52.9%

Johnson & Johnson+8.1%

Gilead Sciences+3.5%

By net margin

Gilead Sciences30.99%+10.2pp

Johnson & Johnson21.48%-3.5pp

UroGen Pharma-94.83%+55.8pp

ImmunityBio, Inc.-606.15%+704pp

CG Oncology-3,682.61%+12,263pp

Profile

CG Oncology is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing oncolytic immunotherapies for bladder cancer. Its core value proposition centers on cretostimogene grenadenorepvec, an investigational therapy designed to eliminate cancer cells through selective replication and the activation of an anti-tumor immune response. The company aims to provide a bladder-sparing alternative to radical surgery for patients with high-risk and intermediate-risk non-muscle invasive bladder cancer.

Competitive position

A late-stage developer of a potential best-in-disease, first-in-class oncolytic immunotherapy for NMIBC, currently transitioning toward commercial-stage operations.

GeographiesUnited States, Asia, Global

Customer segmentsUrologists, Patients with bladder cancer

Business modelBiopharmaceutical R&D

SuppliersContract manufacturing organizations, Clinical trial sites, Raw material suppliers for viral vectors

CustomersSpecialty urology clinics, Medical oncologists, Healthcare providers

CountryUnited States of America

Listed2024

Employees61.0

CEOArthur Kuan

SectorHealthcare

IndustryBiotechnology

Websitecgoncology.com

FilingsSEC EDGAR

Ask your AI about CG Oncology.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CG Oncology's market cap?: CG Oncology (CGON) has a market capitalization of $6.5B and trades on NASDAQ.
What is CG Oncology's revenue and profitability?: CG Oncology generated $5.1M in trailing twelve-month revenue with a net loss of $186.7M, representing a net margin of -3682.6%, with free cash flow of -$160.4M. These figures are based on the Q1 2026 filing.
Who are CG Oncology's competitors?: CG Oncology's key competitors include ImmunityBio Inc., Johnson & Johnson, UroGen Pharma, Inc., and others. These companies compete in similar markets and product categories.
Who does CG Oncology partner with?: CG Oncology's notable partners include Kissei Pharmaceutical Co., Ltd., Lepu Biotech Co., Ltd., Merck & Co., Inc., and others.
What subsidiaries does CG Oncology have?: CG Oncology's subsidiaries include Biovire.
Where is CG Oncology headquartered?: CG Oncology is headquartered in United States of America and employs approximately 61 people. It has been publicly traded since 2024.